Evaxion Biotech A/S (EVAX) Balance Sheet

The erratic movement in total assets suggests that the company's financial foundation is primarily shaped by the timing of equity raises and milestone payments. Investors should monitor whether this volatility stabilizes as the company attempts to transition from a purely research-oriented entity to one with more predictable clinical milestones.

The presence of $7.5M in debt as of 2025Q4 indicates that the firm is increasingly relying on credit facilities to sustain operations. This shift warrants further investigation into the cost of capital and the potential for restrictive covenants that could limit future operational flexibility.

The negative retained earnings balance underscores the long-term nature of the company's clinical development cycle and the lack of self-sustaining profitability. This trend suggests that future equity dilution remains a high probability as the company seeks to bridge the gap toward commercialization.

While the current ratio suggests a short-term ability to cover obligations, the underlying cash burn rate remains the primary concern for solvency. The reliance on cash-on-hand to fund ongoing Phase IIb trials implies that the company's liquidity position is highly sensitive to the timing of future clinical readouts.